Compare DexCom, Inc. (DXCM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Revvity Inc — how do they compare? DexCom, Inc. trades at $77.11 (market cap $28.06B), while Revvity Inc trades at $110.75 (market cap $12.42B). The key difference: DexCom, Inc. is far larger — about 2.3× Revvity Inc's market cap, and Revvity Inc pays a 0.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RVTY | |
|---|---|---|
Market Cap | $28.06B | $12.42B |
Sector | Health | Technology |
52-Week High | $89.53 | $117.75 |
52-Week Low | $54.84 | $82.26 |
Enterprise Value | $27.03B | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
RVTY trades at $111.40, up 0.17% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company maintains stable revenue around $2.9B with an 8.26% net income margin, though its P/E ratio of 53.53 suggests premium valuation. Recent news highlights AI integration advances and FDA clearances, supporting growth initiatives.
Outlook is cautiously optimistic with strong analyst buy ratings (51.72%) and a $111.43 consensus target, but high valuation and margin pressures pose risks. Earnings on August 4, 2026, will be critical for confirming growth trajectory amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
